These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. Vallon-Christersson J, Cayanan C, Haraldsson K, Loman N, Bergthorsson JT, Brøndum-Nielsen K, Gerdes AM, Møller P, Kristoffersson U, Olsson H, Borg A, Monteiro AN. Hum Mol Genet; 2001 Feb 15; 10(4):353-60. PubMed ID: 11157798 [Abstract] [Full Text] [Related]
23. Effects on human transcriptome of mutated BRCA1 BRCT domain: a microarray study. Iofrida C, Melissari E, Mariotti V, Guglielmi C, Guidugli L, Caligo MA, Pellegrini S. BMC Cancer; 2012 May 30; 12():207. PubMed ID: 22646717 [Abstract] [Full Text] [Related]
27. Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Wu LC, Wang ZW, Tsan JT, Spillman MA, Phung A, Xu XL, Yang MC, Hwang LY, Bowcock AM, Baer R. Nat Genet; 1996 Dec 30; 14(4):430-40. PubMed ID: 8944023 [Abstract] [Full Text] [Related]
28. Phosphopeptide interactions with BRCA1 BRCT domains: More than just a motif. Wu Q, Jubb H, Blundell TL. Prog Biophys Mol Biol; 2015 Mar 30; 117(2-3):143-148. PubMed ID: 25701377 [Abstract] [Full Text] [Related]
29. Trans-activation-based risk assessment of BRCA1 BRCT variants with unknown clinical significance. Langerud J, Jarhelle E, Van Ghelue M, Ariansen SL, Iversen N. Hum Genomics; 2018 Nov 20; 12(1):51. PubMed ID: 30458859 [Abstract] [Full Text] [Related]
32. The BRCT domain is a phospho-protein binding domain. Yu X, Chini CC, He M, Mer G, Chen J. Science; 2003 Oct 24; 302(5645):639-42. PubMed ID: 14576433 [Abstract] [Full Text] [Related]
33. Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays. Lee MS, Green R, Marsillac SM, Coquelle N, Williams RS, Yeung T, Foo D, Hau DD, Hui B, Monteiro AN, Glover JN. Cancer Res; 2010 Jun 15; 70(12):4880-90. PubMed ID: 20516115 [Abstract] [Full Text] [Related]
35. Multifunctional transcription factor TFII-I is an activator of BRCA1 function. Tanikawa M, Wada-Hiraike O, Nakagawa S, Shirane A, Hiraike H, Koyama S, Miyamoto Y, Sone K, Tsuruga T, Nagasaka K, Matsumoto Y, Ikeda Y, Shoji K, Oda K, Fukuhara H, Nakagawa K, Kato S, Yano T, Taketani Y. Br J Cancer; 2011 Apr 12; 104(8):1349-55. PubMed ID: 21407215 [Abstract] [Full Text] [Related]
36. Kinetic analysis of interaction of BRCA1 tandem breast cancer c-terminal domains with phosphorylated peptides reveals two binding conformations. Nominé Y, Botuyan MV, Bajzer Z, Owen WG, Caride AJ, Wasielewski E, Mer G. Biochemistry; 2008 Sep 16; 47(37):9866-79. PubMed ID: 18717574 [Abstract] [Full Text] [Related]
37. Comparison of BRCT domains of BRCA1 and 53BP1: a biophysical analysis. Ekblad CM, Friedler A, Veprintsev D, Weinberg RL, Itzhaki LS. Protein Sci; 2004 Mar 16; 13(3):617-25. PubMed ID: 14978302 [Abstract] [Full Text] [Related]
38. Detection of protein folding defects caused by BRCA1-BRCT truncation and missense mutations. Williams RS, Chasman DI, Hau DD, Hui B, Lau AY, Glover JN. J Biol Chem; 2003 Dec 26; 278(52):53007-16. PubMed ID: 14534301 [Abstract] [Full Text] [Related]
39. Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure. Joo WS, Jeffrey PD, Cantor SB, Finnin MS, Livingston DM, Pavletich NP. Genes Dev; 2002 Mar 01; 16(5):583-93. PubMed ID: 11877378 [Abstract] [Full Text] [Related]